🔬 **Cytiva’s Sefia platform** simplifies processes through automation. Ori Biotech’s IRO platform enhances scalability and lowers failure rates.
💧 **Aldevron enhances plasmid purity** with new purification technologies. Assays ensure treatment safety and efficacy. Automation also addresses analytical bottlenecks, promoting better production quality.
Introduction:
The article discusses advancements in the production of cell and gene therapies (CGTs) aimed at enhancing speed and reducing costs. As the demand for these therapies grows, the article explores innovative approaches and technologies that companies implement to improve the efficiency and scalability of manufacturing processes.
- The complexity of CGT manufacturing necessitates the development of specialized platforms that can handle diverse therapeutic processes, like Cytiva’s Sefia platform, designed to automate the workflow.
- Partnerships with industry leaders, such as Kite and Cellular Origins, have helped enhance the Sefia platform by integrating robotic automation, improving scalability and efficiency in production.
- Ori Biotech’s IRO platform focuses on automating various steps in the production of CGTs, aiming to reduce failure rates from 40% to less than 5% while cutting production time and costs significantly.
- Aldevron addresses challenges in DNA plasmid production, essential for gene therapy, by implementing novel membrane technologies for purification, enabling higher quality and scalability.
- Thermo Fisher Scientific and Lonza are developing advanced assays and automated analytics to enhance quality control, mitigate contamination risks, and ensure compliance during therapy manufacturing.
Conclusion:
The advancements in CGT production highlighted in the article indicate a robust effort to streamline manufacturing processes through innovative technologies and collaborative partnerships. By reducing failure rates, improving scalability, and ensuring higher quality standards, these developments are pivotal in making CGTs more accessible and affordable, ultimately benefiting patient care in this rapidly evolving field.
